Neuron Specific Enolase (NSE)
| Product Name | Neuron Specific Enolase |
| Source | Human Brain |
| Catalogue Number | 430-11 |
| Purity | > 96% (SDS-PAGE) |
| Form | Liquid |
| Protein | > 0.5 mg/mL (A280 E0.1%=1.22) |
| Activity | Enzymatically active |
| Formulation | Solution in sodium phosphate, sodium chloride and magnesium sulfate, pH 7.4. |
| Appearance | Clear, colorless liquid |
| Related Products | 151-10 - Carcinoembryonic Antigen from human liver - Liquid 151-09 - Carcinoembryonic Antigen from human liver - Lyophilized 151-53 - Cancer Antigen 15-3 from human ascites fluid |
| Storage | -20°C |
| Recertification | 5 years |
| Synonyms | 2-Phospho-D-glycerate hydro-lyase, NSE, Enolase 2, Gamma-enolase; |
| Molecular Weight | ~45,000 |
| CAS Number | 9014-08-8 |
| E.C. Number | 4.2.1.11 |
| Gene | ENO2, NSE |
| Gene ID | 2026 |
| Accession No | P09104 |
Lee Biosolutions is the leading supplier of human brain Human Neuron Specific Antigen (NSE) for clinical research and diagnostic manufacturing.
Custom preparations, technical support, bulk quantities and aliquoting available, email Info@leebio.com for more details.
Associated Tumor Types: Small-Cell Carcinoma Neuroendocrine Tumor Breast Cancer
According to current literature, NSE is a glycolytic enzyme that catalyzes the conversion of phosphoglycerate to phosphoenol pyruvate and is present in neurons, neuroendocrine cells, and amine precursor uptake and decarboxylation (APUD) cells.
Neuron-specific enolase (NSE) is a neuronal form of the glycolytic enzyme enolase, which was first found in extracts of brain tissue, and was later shown to be present in APUD (amine precursor uptake and decarboxylation) cells and neurons of the diffuse neuroendocrine system but not in other peripheral cells. NSE is a valuable tumor marker for cancers of neuroendocrine origin, especially for small-cell lung cancer and neuroblastoma.
Elevated concentrations are observed in patients with neuroblastoma, pancreatic islet cell carcinoma, medullary thyroid carcinoma, pheochromocytoma, and other neuroendocrine tumors as well as in certain benign conditions. NSE levels are frequently increased in patients with SCLC and infrequently in patients with non-SCLC. NSE has therefore been used to monitor disease progression and management in SCLC.
Lee Biosolutions, Inc
